In an exclusive interview with Generics Bulletin, Talat Imran, CEO of oral-dose biologics player Rani Therapeutics, talks adalimumab, partnering opportunities and financing, in the wake of kicking off pre-clinical development of its RT-111 proposed biosimilar to Janssen’s Stelara (ustekinumab) contained in its proprietary RaniPill Go ‘robotic’ capsule.

Hyloris Pharmaceuticals’ new idiopathic rhinitis treatment sets it on track to achieve its target of around 30 portfolio assets by the end of 2024. 

Stada has begun work on a facility in Romania into which the German giant is investing more than €50m to bolster the European supply chain.

Zentiva gains semi-exclusive commercialization rights to Biocon’s liraglutide drug-device combination in 30 countries, following a string of similar deals for the company since its 2018 acquisition.

Two acquisitions of brands in as many months, Lupin has stepped up its game in the Americas. A buyout of nine established Bausch Health brands follows rights to two from Sunovion. While it awaits news on generic(g) Spiriva, the launch of gPerforomist will help expand Lupin’s respiratory franchise

Teva’s new partnerships will make patient data from its digital inhalers more accessible to healthcare providers, potentially placing Teva’s asthma platform at the forefront of emerging treatment paradigms.

Stada has begun work on a facility in Romania into which the German giant is investing more than €50m to bolster the European supply chain.

One-off opportunities lift Alembic’s US generics business in the fiscal second quarter but the market continues to pose challenges amid surging oversupply and price erosion. On the other hand, a string of injectable approvals, including for ketorolac tromethamine, could open up opportunities for the company given the 'on and off' shortages.

In a busy period for Lannett, the company has benefited from a US shortage of generic Adderall rivals as well as a “more favorable pricing environment” to enjoy better results than expected – albeit with sales still significantly down on last year.

Advanz has identified three key spaces in which it is seeking to generate value: innovative assets, M&A and existing commercial infrastructure.

Even as two biosimilar filings in Europe are stuck due to a lack of inspection staff and a biosimilar could be approved in the UK without a Phase III trial, Aurobindo has licensed novel drug Ryzneuta from Yifan Pharma. Meanwhile, a $650m-$700m revenue forecast for the specialty business has been pushed back as both overall revenues and profits declined during Q2.

Sun Pharmaceuticals continues to dominate the Indian pharmaceutical space while its R&D costs are set to rise.

Major leadership changes are being made at the top of Alvotech, with founder Robert Wessman stepping in to replace Mark Levick as CEO at the same time as Teva’s former head of global R&D, Hafrun Fridriksdottir, becomes COO of the biosimilars developer.

Stada has announced a change in management for its emerging markets division, with Sanofi’s Stéphane Jacqmin joining the firm from the start of 2023 to replace Carsten Cron, who is leaving the German generics and biosimilars giant for pastures new.

With Teva clearing up early who will replace outgoing president and CEO Kåre Schultz, Generics Bulletin looks at five issues that await his replacement, the former Sandoz head Richard Francis.